

RESEARCH ARTICLE

Determination of Pramipexole Dihydrochloride in Tablet Dosage Forms by Visible Spectrophotometric Method Using Acetyl Acetone-Formaldehyde Reagent

*Chemical Sciences
Journal, Vol. 2012:
CSJ-49*

Determination of Pramipexole Dihydrochloride in Tablet Dosage Forms by Visible Spectrophotometric Method Using Acetyl Acetone-Formaldehyde Reagent

P Lavudu*¹, AP Rani², CB Sekaran³, KS Kumar⁴, A Ramesh⁵

¹Department of Pharmaceutical Biotechnology, Sitha Institute of Pharmaceutical Sciences, Hyderabad (AP), India.

²University College of Pharmaceutical Sciences, Acharya Nagarjuna University, Guntur (AP), India.

³Department of Biotechnology, JKC College, Guntur (AP), India.

⁴Department of Pharmaceutics, Sitha Institute of Pharmaceutical Sciences, Hyderabad (AP), India.

⁵Department of Pharmacology, Sitha Institute of Pharmaceutical Sciences, Hyderabad (AP), India.

*Correspondence to: Petikam Lavudu, plavudu@yahoo.com

Accepted: June 7, 2012; Published: June 20, 2012

Abstract

A simple and sensitive visible spectrophotometric method has been developed for the determination of pramipexole dihydrochloride (PPD). The method is based on the condensation of the drug with acetyl acetone and formaldehyde producing a yellow colored Hantzsch condensation product having maximum absorption at 455 nm. The method is optimized for pH, concentration of reagents (acetyl acetone and formaldehyde) required, temperature and heating time. Beer's law was obeyed in the concentration range of 5–150 $\mu\text{g mL}^{-1}$. Molar absorptivity, Sandell's sensitivity, limit of detection and limit of quantification were calculated and were found to be $5.23 \times 10^3 \text{ L mole}^{-1} \text{ cm}^{-1}$, $0.0849 \mu\text{g cm}^{-2}$, $0.449 \mu\text{g mL}^{-1}$, and $1.362 \mu\text{g mL}^{-1}$, respectively. The method was applied to different tablet dosage forms containing PPD. The results of the proposed method were compared with the reported UV spectrophotometric method. The new method was found to be simple, accurate (*t*-test), and reproducible (*F*-test).

Keywords: Pramipexole dihydrochloride; Hantzsch reaction; spectrophotometric analysis; tablet dosage forms.

1. Introduction

Pramipexole dihydrochloride (PPD) [1–6], a nonergot dopamine agonist approved in the US (1997), is used as an antidyskinetic for the treatment of Parkinson's disease. Its chemical name is (*S*)-*N*⁶-propyl-4,5,6,7-tetrahydro-1,3-benzothiazole-2,6-diamine dihydrochloride (Figure 1). The ability of PPD to alleviate the signs and symptoms of Parkinson's disease is supposed to be linked to its ability to stimulate dopamine receptors in the striatum.




Figure 1: Structure of pramipexole dihydrochloride.

The therapeutic importance of PPD has encouraged several researchers to develop analytical methods for its determination in bulk, pharmaceutical dosage forms and biological fluids. The methods used for PPD quantification include UV-spectrophotometry [7], thin layer chromatography [8], stability indicating liquid chromatography [9], HPLC with UV detection [10–15], HPLC with electrochemical detection [15], capillary electrophoresis with laser-induced fluorescence detection [16], gradient ultra-fast liquid chromatography [17], HPLC-MS/MS [18–20], GC-MS [21], UPLC-MS/MS [22] and spectrophotometric methods [23, 24]. Most of these methods (except spectrophotometric) require expensive or sophisticated instruments or involve procedures with careful control of the experimental conditions and are not simple for routine analysis. However,

spectrophotometric methods are particularly attractive because of ease in accessibility and their quick applicability to routine analysis. Reagents used for spectrophotometric determination of PPD in bulk and pharmaceutical dosage forms include: N-(1-naphthyl) ethylenediamine hydrochloride (diazocoupling) [23], paradimethylaminobenzaldehyde (condensation reaction) [23], bromocresol green (ion pair complex formation) [24] and bromothymol blue (ion pair complex formation) [24]. The reported spectrophotometric methods suffer from one or more disadvantages like use of carcinogenic reagent, extraction with organic solvent, less sensitivity, and critical working conditions. Hence they are not employed for routine analysis.

The present paper, for the first time, describes a novel, sensitive, simple, accurate and precise visible spectrophotometric method for the determination of PPD in bulk and tablet dosage forms. The proposed method is based on the reaction of the PPD with acetylacetone-formaldehyde reagent to produce a yellow colored species having absorption maxima at 455 nm. The results of the analysis were validated by statistical analysis and recovery studies. Common additives used as excipients in the tablet dosage forms do not interfere in the determination of the PPD.

2. Methods

2.1. Instrumentation

All spectrophotometric measurements were carried out using an Elico (Hyderabad, India) double beam model SL 159 digital spectrophotometer. The cells used for absorbance measurements were 1-cm matched quartz cells. Elico (Hyderabad, India) LI120 model pH meter was used for pH measurements. Kemi KWB 220 model water bath (Ernakulam, India) was used to control the temperature for color development. Samples were weighed by using Essae-Teraoka electronic weighing balance (Goa, India) PG1000 model.

2.2. Reagents

All chemicals used were of analytical reagent grade and used as received. Double distilled water was used in the preparation of all solutions. All the solutions were prepared afresh daily. Acetate buffer (pH 5) was prepared by dissolving 1.36 g of sodium acetate (Qualigens Fine Chemicals, Mumbai) and 6 mL of glacial acetic acid (Qualigens Fine Chemicals, Mumbai) in sufficient water to produce 100 mL. 8.4% Acetylacetone solution was freshly prepared by mixing 8.4 mL of acetyl acetone (Sdfine-Chem Limited, Mumbai) with 40 mL of acetate buffer (pH 5) and diluted to 100 mL with distilled water. 20% Formaldehyde was prepared by mixing 20 mL of 40% formaldehyde (Fisher Scientific, Mumbai) with 40 mL of acetate buffer (pH 5) and diluted to 100 mL with distilled water.

2.2.1. Standard solutions of pramipexole dihydrochloride

Pharmaceutical grade PPD was kindly gifted by Matrix Laboratories, Hyderabad, India, and was used as received. A stock standard solution containing 1 mg mL^{-1} of PPD was prepared in water. Working standard solution equivalent to 500 (proposed method) and 400 (reference method) $\mu\text{g mL}^{-1}$ of PPD was obtained by appropriate dilution of stock solution with water.

2.3. Tablet dosage forms of pramipexole dihydrochloride

Tablet dosage forms of PPD such as Parpex (1 mg, Zydus Cadila, Ahmedabad) and Pramipex (0.5 mg and 1 mg, Sun Pharma, Mumbai) were purchased from the local pharmacy market.

2.4. Recommended procedure

Different aliquots (0.1–3.0 mL) of working standard ($500 \mu\text{g mL}^{-1}$) solutions containing 5–150 $\mu\text{g mL}^{-1}$ of PPD was transferred into a series of 10 mL volumetric flasks and the total volume was adjusted to 3 mL with acetate buffer (pH 5). To each flask, 2 mL of 8.4% v/v acetylacetone and 1 mL of 20% formaldehyde reagents were added. The flasks were stoppered and contents were mixed well. The mixture was heated at 70°C for 10 min, cooled and diluted to 10 mL with distilled water. The absorbance of the yellow color solution was measured at 455 nm against the reagent blank prepared similarly omitting the drug. The amount of PPD present in the sample was computed from the corresponding calibration curve.

2.5. Reference method

Different aliquots of working standard solution ($0.1\text{--}1.5\text{ mL}$, $400\ \mu\text{g mL}^{-1}$) of PPD were transferred into a series of 10 mL calibrated flasks and diluted to the mark with water. The absorbance of the solution was measured at 260 nm against the water. The standard calibration curve was prepared to calculate the amount of PPD in unknown samples.

2.6. Analysis of pramipexole dihydrochloride in tablet dosage forms

Fifty tablets were weighed accurately and ground into a fine powder. An amount of powder equivalent to 25 mg of PPD was weighed into a 25 mL volumetric flask; 15 mL of the water was added and shaken thoroughly for about 10 min . The volume was diluted up to the mark with the same solvent, mixed well and filtered using a quantitative filter paper. The filtered solution was appropriately diluted with water. Convenient aliquots were subjected to analysis by the recommended procedure and reference method.

3. Results and Discussion

Hantzsch reaction [25] is a condensation reaction that allows the formation of dihydropyridine derivatives by condensation of an aldehyde with two equivalents of a β -ketoester in the presence of ammonia. In the same manner, acetylacetone (β -ketoester) together with formaldehyde (aldehyde) reacts with aliphatic amines by Hantzsch reaction forming a yellow colored product that can be measured spectrophotometrically or spectrofluorimetrically. The quantification of certain sulpham drugs [26] (sulfacetamide sodium, sulfadiazine, sulfadimidine, and sulfathiazole), kanamycin [27], lisinopril [28], gabapentin [29], cefrozil [29], tranexamic acid [30], and sitagliptin phosphate [31] in its bulk and pharmaceutical dosage forms were carried out using Hantzsch reaction.

The results obtained in the proposed method were based on the condensation of primary amino group of PPD with acetyl acetone, as β -diketone, and formaldehyde, as an aldehyde, producing a yellow colored product having maximum absorption at 455 nm (Figure 2). The probable reaction mechanism is shown in Figure 3.

3.1. Optimization of experimental variables

3.1.1. Effect of pH

The effect of pH on the Hantzsch condensation reaction is shown in Figure 4. This figure reveals that the absorbance of the Hantzsch condensation product increases in the media of pH from $3.5\text{--}5$ and there is a decrease in the absorbance with the further rise in pH. Keeping in view the reproducibility and stability of the Hantzsch condensation product, a pH of 5 was considered optimum throughout the determination process.




Figure 2: Absorption spectrum of Hantzsch condensation product.




Figure 3: Proposed reaction scheme for the formation of Hantzsch condensation product.




Figure 4: Effect of pH on the absorbance of Hantzsch condensation product.

3.1.2. Effect of acetylacetone

In order to fix the concentration of acetyl acetone, the absorbance of the solution containing fixed concentration of PPD ($50 \mu\text{g mL}^{-1}$) and 20% formaldehyde (1 mL) and varying volumes of 8.4% acetyl acetone (0.5–4.0 mL) was recorded in a media of pH 5. It is obvious from Figure 5 that the maximum absorbance was obtained with 2 mL of 8.4% acetyl acetone; above this volume, the absorbance remained unchanged. Therefore, 2 mL 8.4% acetyl acetone was considered sufficient for the condensation reaction.




Figure 5: Effect of acetylacetone on the absorbance of Hantzsch condensation product.

3.1.3. Effect of formaldehyde

In order to fix the concentration of formaldehyde, the absorbance of the solution containing fixed concentration of PPD ($50 \mu\text{g mL}^{-1}$) and 8.4% acetyl acetone (2 mL) and varying volumes (0.5–4.0 mL) of 20% formaldehyde was recorded in a media of pH 5. The results showed that 1 mL of 20% formaldehyde was sufficient for the condensation reaction (Figure 6). Thus, 1 mL of 20% formaldehyde was chosen for the procedure. The presence of excess of the formaldehyde does not alter the absorbance of the reaction.




Figure 6: Effect of formaldehyde on the absorbance of Hantzsch condensation product.

3.1.4. Effect of temperature and heating time

No color was developed at room temperature. The effect of temperature was studied in the range of 30–100°C. The absorbance and reaction rate increased with increasing temperature up to 70°C, and higher temperature had negative effect (Figure 7). Therefore, 70°C was selected as the optimum temperature.




Figure 7: Effect of temperature on the formation of Hantzsch condensation product.

In order to obtain the highest and most stable absorbance, the effect of heating time on the condensation reaction was catalyzed by heating the reaction solution in a water bath at 70°C for 5–30 min. The time required for the completion of the reaction and maximum absorbance was obtained after 10 min of heating and remained constant up to 30 min (Figure 8). Therefore, the optimum heating time was fixed at 10 min.




Figure 8: Effect of heating time on the formation of Hantzsch condensation product.

3.2. Stability of Hantzsch condensation product

To study the stability of Hantzsch condensation product, the absorbance values of the reaction solution, after diluting, was measured at regular intervals of time. It was found that the absorbance remained constant at least for 4.5 hr. This suggests that the condensation product was stable for a period of 4.5 hr.

3.3. Analytical data

Under the optimized experimental conditions, a series of solutions containing fixed concentration of the reagent and varying concentration of PPD in the media of pH 5 media was prepared. The absorbance values were measured at 455 nm against reagent blank solution. Linear analytical curve shown in the Figure 9 indicates that PPD can be determined in the concentration range 5–150 $\mu\text{g mL}^{-1}$. The analytical curve for the determination of PPD can be fitted into the equation:

$$A_{455\text{ nm}} = 0.0116C + 0.0309$$

where A is absorbance and C is concentration of PPD in $\mu\text{g mL}^{-1}$.

The correlation coefficient was 0.9986. The molar absorptivity and Sandell's sensitivity were found to be $5.23 \times 10^3 \text{ L mol}^{-1} \text{ cm}^{-1}$ and $0.0849 \mu\text{g cm}^{-2}$ respectively. The limits of detection and quantification were found to be 0.449 and $1.362 \mu\text{g mL}^{-1}$, respectively.




Figure 9: Linearity curve for the proposed method.

The intraday accuracy and precision of the proposed methods was determined by measuring the content of PPD in pure form at three different concentration levels (10, 80, and $140 \mu\text{g mL}^{-1}$). The intraday precision and accuracy of the proposed method was performed by carrying out five independent analyses at each concentration level within one day. The results of standard deviation (SD), relative standard deviation (RSD), percent of error and recoveries by the proposed method in Table 1 reveal that the proposed method was reasonably accurate and precise.

Table 1: Results of intraday precision and accuracy of the proposed method.

Concentration of PPD ($\mu\text{g mL}^{-1}$)		RSD (%)	Recovery (%)	Error (%)
Taken	Found \pm SD (n = 5)			
10	9.95 ± 0.084	0.844	99.50	0.50
80	79.97 ± 0.592	0.740	99.96	0.03
140	140.10 ± 0.637	0.456	100.07	0.71

In order to further access the accuracy of the proposed method and to check the interference from excipients used in the formulations, recovery experiments were carried out by standard addition method. For this purpose, a known amount of pure PPD was added to pre-analyzed tablets and the total value of drug was estimated by the proposed method. The results (Table 2) were reproducible with low SD and RSD. No interference from the common pharmaceutical excipients was observed.

Table 2: Experimental values obtained in recovery test for PPD tablets by proposed method.

Formulation	Labeled claim (mg)	Concentration of PPD (mg)		RSD (%)	Recovery (%)
		Added	Found \pm SD (n = 5)		
Parpex	1.0	0.50	1.47 \pm 0.0057	0.387	98.00
Pramipex	1.0	0.50	1.52 \pm 0.0064	0.421	101.33
Pramipex	0.5	0.25	0.78 \pm 0.0035	0.448	104.00

3.4. Application of the proposed method

The proposed method was applied to the determination of PPD in two brands of tablets, Parpex (1 mg, Zydus Cadila, Ahmedabad) and Pramipex (0.5 mg and 1 mg, Sun Pharma, Mumbai). The results obtained by the proposed method were statistically compared with those of the literature (UV-Spectrophotometry) method [7] by applying Student's *t*-test for accuracy and *F*-test for precision. The results of this study given in Table 3 reveal that the calculated *t*- and *F*-values did not exceed the tabulated values at the 95% confidence level, suggesting that the proposed method and the literature method did not differ significantly with respect to accuracy and precision.

Table 3: Determination of PPD in tablet dosage forms by proposed and reference methods.

Formulation	Labeled claim (mg)	Found (mg) \pm SD (n = 5)		t Value	F value
		Proposed method	Reference method		
Parpex	1.0	1.020 \pm 0.0086 % R = 102.0 RSD = 0.843	0.995 \pm 0.0036 % R = 99.50 RSD = 0.361	1.38	2.41
Pramipex	1.0	0.998 \pm 0.0049 % R = 99.80 RSD = 0.490	0.997 \pm 0.0028 % R = 99.70 RSD = 0.280	1.43	2.59
Pramipex	0.5	0.495 \pm 0.0073 % R = 99.50 RSD = 1.470	0.502 \pm 0.0038 % R = 100.40 RSD = 0.756	1.67	2.62

R – Recovery.

*Tabulated *t* value at 95 % confidence level = 2.77 and Tabulated *F* value at 95% confidence level = 6.39.

4. Conclusion

A new visible spectrophotometric method based on the Hantzsch condensation of drug with acetylacetone-formaldehyde reagent was developed for the determination of PPD in tablet dosage form. The method is quite simple and do not require expensive or sophisticated instruments, pre-treatment of the drug, extraction with organic solvent and critical working conditions. The method has wider linear range with good precision and accuracy. Hence, the proposed method can be applied for routine analysis and in quality control laboratories for determination of PPD in bulk and tablet dosage forms.

Competing Interests

The authors declare that they have no competing interests.

Authors' Contributions

PL carried out the analytical studies; APR carried out the statistical analysis; CBS drafted the manuscript; AR carried out the sequence alignment; KTS participated in analytical studies and helped to draft the manuscript.

References

1. Hoerger TJ, Bala MV, Rowland C, *et al.*, 1998. Cost effectiveness of pramipexole in Parkinson's disease in the US. *Pharmaco Economics*, 14: 541–557.

2. Bennett JP, Piercey MF, 1999. Pramipexole - a new dopamine agonist for the treatment of Parkinson's disease. *Journal of Neurological Sciences*, 163: 25–31.
3. Kohno Y, Takeuchi S, 2004. Pharmacological profiles and clinical effects of antiparkinsonian agent pramipexole. *Nippon Yakurigaku Zasshi*, 123: 429–440.
4. Mierau J, Schneider FJ, Ensinger HA, *et al.*, 1995. Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors. *European Journal of Pharmacology*, 290: 29–36.
5. Kvernmo T, Härtter S, Burger E, 2006. A review of the receptor-binding and pharmacokinetic properties of dopamine agonists. *Clinical Therapeutics*, 28: 1065–1078.
6. Millan MJ, Maiorini L, Cussac D, *et al.*, 2002. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. *The Journal of Pharmacology and Experimental Therapeutics*, 303: 791–804.
7. Srinu Babu G, Raju CAI, 2007. Spectrophotometric determination of pramipexole dihydrochloride monohydrate. *Asian Journal of Chemistry*, 19: 816–818.
8. Pawar SM, Dhaneshwar SR, 2011. Application of stability indicating high performance thin layer chromatographic method for quantitation of pramipexole in pharmaceutical dosage form. *Journal of Liquid Chromatography & Related Technologies*, 34: 1664–1675.
9. Vedavati MP, Aniket PS, Jaiprakash NS, *et al.*, 2011. Stability-indicating HPLC determination of pramipexole dihydrochloride in bulk drug and pharmaceutical dosage form. *Journal of Brazilian Chemical Society*, 22: 1253–1258.
10. Seshagiri Rao JVLN, Anantha Kumar D, Mastanamma S, *et al.*, 2009. Estimation of pramipexole by an RP-HPLC method. *International Journal of Chemical Sciences*, 7: 2789–2794.
11. Pathare DZ, Jadhav AS, Shingare MS, 2006. Validated chiral liquid chromatographic method for the enantiomeric separation of pramipexole dihydrochloride monohydrate. *Journal of Pharmaceutical and Biomedical Analysis*, 16: 1152–1156.
12. Jančić B, Medenica M, Ivanović D, *et al.*, 2007. Experimental design in chromatographic analysis of pramipexole and its impurities. *Acta Chimica Slovenica*, 54: 49–54.
13. Jančić B, Medenica M, Ivanović D, *et al.*, 2007. Chromatographic determination of dissociation constants of pramipexole and its impurities. *Chromatographia*, 65: 633–635.
14. Srinubabu G, Jaganbabu K, Sudharani B, *et al.*, 2006. Development and validation of a LC method for the determination of pramipexole using an experimental design. *Chromatographia*, 64: 95–100.
15. Yau YL, Glenn DH, Nita I, 1996. Determination of pramipexole in human plasma and urine by high-performance liquid chromatography with electrochemical and ultraviolet detection. *Journal of Chromatography B, Biomedical Sciences and Applications*, 683: 217–223.
16. Alessandro M, Ernst K, Emanuele M, *et al.*, 2008. Analysis of the anti-Parkinson drug pramipexole in human urine by capillary electrophoresis with laser-induced fluorescence detection. *Analytica Chimica Acta*, 626: 89–96.
17. Syeda H, Akalanka D, Appala Raju S, *et al.*, 2010. Gradient ultra-fast liquid chromatographic analysis of pramipexole and its application to drug quality control. *Der Pharmacia Lettre*, 2: 315–325.
18. Yau YL, Jeffrey MS, Glenn DH, *et al.*, 1996. Determination of pramipexole (U-98,528) in human plasma by high-performance liquid chromatography with atmospheric pressure chemical ionization tandem mass spectrometry. *Journal of Chromatography B: Biomedical Sciences and Applications*, 683: 209–216.
19. Nirogi RV, Kandikere V, Shrivastava W, *et al.*, 2007. Quantification of pramipexole in human plasma by liquid chromatography tandem mass spectrometry using tamsulosin as internal standard. *Biomedical Chromatography*, 21: 1151–1158.
20. Bharathi DV, Hotha KK, Sagar PV, *et al.*, 2009. Development and validation of a sensitive LC-MS/MS method with electrospray ionization for quantitation of pramipexole in human plasma: application to a clinical pharmacokinetic study. *Biomedical Chromatography*, 23: 212–220.
21. Jayesh G, Ravindra V, Shobhana K, *et al.*, 2011. Development and validation of GC/MS method for determination of pramipexole in rat plasma. *Biomedical Chromatography*, 25: 524–530.
22. Yadav M, Rajasekhar R, Kurani H, *et al.*, 2010. Validated ultra-performance liquid chromatography tandem mass spectrometry method for the determination of pramipexole in human plasma. *Journal of Chromatographic Science*, 48: 811–818.

23. Gurupadaya BM, Vishwajith V, Srujana N, 2009. Spectrophotometric methods for the estimation of pramipexole dihydrochloride in pharmaceutical formulations. *World Journal of Chemistry*, 4: 157–160.
24. Thangabalan B, Kumar DP, Lavanya G, *et al.*, 2011. Extractive spectrophotometric determination of pramipexole dihydrochloride in pure and pharmaceutical formulations. *Journal of Pharmacy Research*, 4: 813–814.
25. Hantzsch A, 1881. Condensation produkte aus Aldehyd ammoniak and Ketoniartigen Verbindungen. *Chemische Berichte*, 14: 1637–1638.
26. Amin AS, Zareh MM, 1996. Acetylacetone-formaldehyde reagent for the spectrophotometric determination of some sulfa drugs in pure and dosage forms. *Microchimica Acta*, 124: 227–233.
27. Ahmad AS, Hoda NMD, Ahmad M, 2006. A simple and selective kinetic spectrophotometric method for the determination of kanamycin using acetylacetone-formaldehyde reagent in N,N'-dimethylformamide medium. *Journal of Analytical Chemistry*, 61: 870–874.
28. El-Yazbi FA, Abdine HH, Shaalan RA, 1999. Spectrophotometric and spectrofluorometric methods for the assay of lisinopril in single and multicomponent pharmaceutical dosage forms. *Journal of Pharmaceutical and Biomedical Analysis*, 19: 819–827.
29. Ayad MM, El-Henawee MM, Abdellatef HE, 2005. Spectrophotometric and spectrofluorimetric determination of gabapentin and cefprozil monohydrate using acetylacetone and formaldehyde. *Alexandria Journal of Pharmaceutical Sciences*, 9: 157–161.
30. El-Aroud KA, Abushoffa AM, Abdellatef HE, 2007. Spectrophotometric and spectrofluorimetric methods for the determination of tranexamic acid in pharmaceutical formulation. *Chemical and Pharmaceutical Bulletin*, 55: 364–367.
31. Bala Sekaran C, Prameela Rani A, 2010. Development and validation of spectrophotometric method for the determination of DPP-4 inhibitor sitagliptin in its pharmaceutical preparations. *Eletica Química*, 35: 45–53.